☆ 4.5 Article

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets A MAGNIFY-MS Substudy

Heinz Wiendl et al.

Summary: Cladribine tablets cause a reduction in lymphocytes, with a predominant effect on B-cell and T-cell counts. The MAGNIFY-MS substudy reports the dynamic changes on multiple peripheral blood mononuclear cell (PBMC) subtypes and immunoglobulin (Ig) levels over 12 months after the first course of cladribine tablets in patients with highly active relapsing multiple sclerosis (MS).

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Add to Collection

Article Clinical Neurology

Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers

Mario Habek et al.

Summary: Based on the CLARITY study, cladribine tablets were approved for use in the EU in 2017 as a high-efficacy therapy for highly active relapsing-remitting MS. Limited evidence exists on managing patients beyond 4 years after cladribine treatment. Postapproval data show that two cycles of cladribine effectively control disease activity in the long term. Retreatment with cladribine may benefit patients with minimal or moderate disease activity, while switching to another high-efficacy treatment is recommended for patients with significant disease activity or progression.

NEUROLOGY AND THERAPY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4

Sven G. Meuth et al.

Summary: Oral cladribine is an effective therapy for relapsing multiple sclerosis. Continuous monitoring of disease activity is important for managing patients beyond year 4, and treatment decisions should be based on clinical and radiological evaluation.

EXPERT OPINION ON PHARMACOTHERAPY (2022)

Add to Collection

Article Clinical Neurology

Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis MAGNIFY-MS

Nicola de Stefano et al.

Summary: The study found that cladribine tablets can rapidly reduce active brain lesions in MS patients after treatment initiation, indicating its early onset of action.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)

Add to Collection

Article Clinical Neurology

Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

Peter Rieckmann et al.

Summary: This summary discusses the findings from a previously published article that provides recommendations for COVID-19 vaccinations in multiple sclerosis (MS) patients taking cladribine tablets. The results suggest that MS patients taking cladribine tablets should receive the COVID-19 vaccine as soon as possible, as it is considered safe and effective without interference from the medication.

NEURODEGENERATIVE DISEASE MANAGEMENT (2022)

Add to Collection

Article Clinical Neurology

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

Jose Fernandez-Velasco et al.

Summary: Ocrelizumab induced changes in immune cell distribution in patients with primary progressive MS, reducing inflammatory cells and leading to a decrease in sNfL levels.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

Add to Collection

Review Clinical Neurology

Highly effective disease-modifying treatment as initial MS therapy

Klaus Schmierer et al.

Summary: The use of highly effective compounds (HE) as the initial therapy for multiple sclerosis (pwMS) has become popular, with evidence suggesting that early use of HE DMT is superior to a slow treatment escalation approach and delays in HE DMT could lead to more rapid and irreversible disability accrual. The risk profile of most HE DMTs is predictable and manageable, supporting the idea that the associated risks should not hinder the adoption of HE DMT as a default strategy.

CURRENT OPINION IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment

Leoni Rolfes et al.

Summary: Skin-related adverse events are common in multiple sclerosis patients treated with cladribine, with hair thinning, skin rash, mucositis, and pruritus being the most commonly observed reactions within the first 3 months of treatment. Additionally, herpes virus infections were reported in 15% of patients, with severe cases requiring hospitalization. Further monitoring and interdisciplinary support are necessary for early detection and management of skin AEs in cladribine-treated patients.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

Add to Collection

Article Clinical Neurology

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis Data From 2 Different National Strategies

Tim Spelman et al.

Summary: This study investigated the association between national differences in treatment strategies for RRMS and disability outcomes, finding that the Swedish treatment strategy was associated with reduced rates of disability worsening compared to the Danish strategy.

JAMA NEUROLOGY (2021)

Add to Collection

Review Clinical Neurology

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice

Peter Rieckmann et al.

Summary: An international consensus-based program led by MS experts provided timely recommendations on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Through expert opinions and available evidence, consensus was achieved on 13 recommendations, addressing issues such as patient selection, timing and efficacy, and safety related to COVID-19 vaccination for MS patients receiving cladribine tablets.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients

Kimberley Allen-Philbey et al.

Summary: The study reported on the safety and effectiveness of subcutaneous cladribine in multiple sclerosis patients, showing that cladribine was generally well tolerated and effective in both relapsing and progressive MS patients, suggesting it may be a viable treatment option for MS patients at different disease stages.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

Add to Collection

Letter Clinical Neurology

Health-care disparities for people with multiple sclerosis

Joanna Laurson-Doube et al.

LANCET NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

Anna He et al.

LANCET NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Severe skin reactions associated with cladribine in people with multiple sclerosis

M. Mateo-Casas et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement?

Kimberley Allen-Philbey et al.

FRONTIERS IN NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS

Tobias Moser et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

CSF neurofilament light chain testing as an aid to determine treatment strategies in MS

Saul Reyes et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Article Clinical Neurology

Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis

T. Leist et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

Gavin Giovannoni et al.

MULTIPLE SCLEROSIS JOURNAL (2019)

Add to Collection

Article Clinical Neurology

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

Gavin Giovannoni et al.

MULTIPLE SCLEROSIS JOURNAL (2019)

Add to Collection

Review Clinical Neurology

Potential mechanisms of action related to the efficacy and safety of cladribine

David Baker et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)

Add to Collection

Editorial Material Clinical Neurology

Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis

Daniel M. Hartung et al.

JAMA NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies

Zhifeng Mao et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)

Add to Collection

Article Clinical Neurology

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis

Dayo Afolabi et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Article Clinical Neurology

Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Gavin Giovannoni et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Article Clinical Neurology

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis

Dayo Afolabi et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Article Clinical Neurology

Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Gavin Giovannoni et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Article Clinical Neurology

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells

Bryan Ceronie et al.

JOURNAL OF NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine

O. Yildiz et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)

Add to Collection

Article Clinical Neurology

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

David Baker et al.

JAMA NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis

Cesar Alvarez-Gonzalez et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2017)

Add to Collection

Review Medicine, General & Internal

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

David Baker et al.

EBIOMEDICINE (2017)

Add to Collection

Article Clinical Neurology

Both cladribine and alemtuzumab may effect MS via B-cell depletion

David Baker et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)

Add to Collection

Review Clinical Neurology

Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity

Erin E. Longbrake et al.

JAMA NEUROLOGY (2016)

Add to Collection

Article Clinical Neurology

Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies

Gavin Giovannoni et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)

Add to Collection

Article Clinical Neurology

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine

Julia Pakpoor et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)

Add to Collection

Article Immunology

Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

Arumugam Palanichamy et al.

JOURNAL OF IMMUNOLOGY (2014)

Add to Collection

Article Biochemical Research Methods

Neurofilament ELISA validation

Axel Petzold et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2010)

Add to Collection

Article Medicine, General & Internal

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

Gavin Giovannoni et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.